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Abstract
Background: Mortality after perforated and bleeding peptic ulcer increases with age. Limited data
exist on how the higher burden of comorbidity among elderly patients affects this association. We
aimed to examine the association of age with short-term mortality after perforated and bleeding
peptic ulcer and to determine the impact of comorbidity on this association.
Methods: In this population-based cohort study in three Danish counties between 1991 and 2003
we identified two cohorts of patients: those hospitalized with a first-time discharge diagnosis of
perforated peptic ulcer and those with bleeding peptic ulcer. The diagnoses were ascertained from
hospital discharge registries and mortality through the Danish Civil Registration System.
Information on comorbidity and use of ulcer-related drugs was obtained through administrative
medical databases. We computed age-, gender- and comorbidity-standardized 30-day mortality
rates and used Cox's regression to estimate adjusted 30-day mortality rate ratios (MRR) for elderly
compared with younger patients.
Results: Among 2,061 patients with perforated peptic ulcer, 743 (36%) were 65–79 years old and
513 patients (25%) were aged 80+ years. Standardized 30-day mortality was 8.9% among patients
younger than 65 years rising to 44.6% among patients aged 80+ years, corresponding to an adjusted
MRR of 5.3 (95% CI: 4.0–7.0). Among 7,232 patients with bleeding peptic ulcer 2,372 (33%) were
aged 80+ years. Standardized 30-day mortality among patients younger than 65 was 4.3% compared
with 16.9% among patients aged 80+ years, corresponding to an adjusted MRR of 3.7 (95% CI: 2.9–
4.7). Analyses stratified by comorbidity consistently showed high MRRs among elderly patients,
regardless of comorbidity level.
Conclusion: Ageing is a strong predictor for a poor outcome after perforated and bleeding peptic
ulcer independently of comorbidity.
Background
The incidence of complicated peptic ulcer disease (PUD),
including perforated and bleeding peptic ulcer, increases
with advanced age [1,2]. This increase has been attributed
Published: 17 April 2007
BMC Geriatrics 2007, 7:8 doi:10.1186/1471-2318-7-8
Received: 6 October 2006
Accepted: 17 April 2007
This article is available from: http://www.biomedcentral.com/1471-2318/7/8
© 2007 Christensen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Geriatrics 2007, 7:8 http://www.biomedcentral.com/1471-2318/7/8
Page 2 of 8
(page number not for citation purposes)
to the high frequency of risk factors for PUD among eld-
erly patients, e.g., Helicobacter pylori colonization or use of
non-steroidal anti-inflammatory drugs (NSAIDs) [3].
Perforated peptic ulcer is a serious condition with an over-
all reported mortality of 5%–25%, rising to as high as
50% with age [4-6]. Being closely related to advanced age,
increased burden of comorbidity may partially explain the
higher mortality among elderly patients. Nevertheless, vir-
tually no data exist on the influence of comorbidity on
age-related increase in mortality of perforated peptic
ulcer.
Despite improvements in the last decades, in monitoring
and treatment, bleeding peptic ulcer carries an unchanged
short-term mortality approaching 10% [7,8]. Previous
studies reported a higher short-term mortality from acute
upper gastrointestinal bleeding including – but not con-
fined to – bleeding peptic ulcer, among elderly compared
with younger patients [9-11]. Again, no study has exam-
ined whether this association between age and mortality
is related to increased burden of comorbidity in elderly
patients.
We conducted this population-based cohort study to
examine to which extent advanced age increased 30-day
mortality of perforated and bleeding peptic ulcer and to
determine the impact of comorbidity on this association.
Methods
This population-based cohort study used data from med-
ical registries in the Danish counties of North Jutland,
Viborg and Aarhus, covering a population of 1.4 million,
which is approximately 25% of the entire Danish popula-
tion.
The Danish National Health Service provides tax-sup-
ported healthcare for all residents, guaranteeing free
access to all general practitioners and hospitals and
refunding a variable proportion of costs of prescribed
medications. In Denmark all acute surgical conditions,
including perforated and bleeding peptic ulcer, are treated
at public hospitals operating under the authority of the
National Health Service.
The different study periods were determined by availabil-
ity of computerized prescription data records in the three
counties, starting from January 1, 1991 in North Jutland,
January 1, 1996 in Aarhus, and January 1, 1998 in Viborg
County, through December 31, 2003 in all counties.
Patients with perforated peptic ulcer and bleeding peptic 
ulcer
Using hospital discharge registries that are merged into a
research database hosted by the Department of Clinical
Epidemiology, Aarhus University Hospital, Denmark, we
identified all patients with a first-time discharge diagnosis
of perforated or bleeding peptic ulcer during the study
period. The discharge registries, established in 1977, con-
tain information on patients' civil registry numbers, dates
of admission and discharge and up to 20 discharge diag-
noses coded by physicians according to the International
Classification of Diseases (ICD) (8th edition until the end
of 1993, 10th edition thereafter). The discharge registries
do not contain data on whether perforated or bleeding
peptic ulcer was the reason for hospitalisation or whether
it occurred as a complication during a hospitalisation
with other diseases. ICD-8 codes utilized for identification
of patients with perforated peptic ulcer were 53100,
53101, 53108, 53109, 53209, 53309, and 53409. The
ICD-10 codes were K251, K252, K255, K256, K261, K262,
K265, K266, K271, K272, K275, K276, K281, K282, K285,
and K286. ICD-8 codes utilized for identification of
patients with bleeding peptic ulcer were 53190, 53192,
53195, 53290, 53390, 53490 and ICD-10 codes were
K250, K254, K260, K264, K270, K274, K280, and K284.
Age and mortality
All Danish citizens are assigned a unique civil registry
number encoding age, gender, and date of birth and death
or migration. This number is included in all Danish
administrative registries and enables unambiguous link-
age between these [12].
To obtain information on death or migration, we linked
the study cohort to the Danish Civil Registration System,
which has kept records for the entire Danish population
since 1968 on vital status [dead, alive], date of death, res-
idence, and migration.
Comorbidity
We used the Charlson comorbidity index as a summary
measure for burden of comorbidity [13]. The Charlson
index includes 19 major disease categories, including car-
diovascular diseases, diabetes, chronic pulmonary, liver,
renal and peptic ulcer disease, and solid and haematolog-
ical malignancies. For computing the Charlson index
score, a weight is assigned to each disease category, and
the score is the sum of these weights. The index has been
adapted and validated for use with hospital discharge reg-
istry data in ICD-based databases for the prediction of
short- and long-term mortality [14]. For each patient we
identified, in the hospital discharge registries, all primary
and secondary discharge diagnoses for all hospitalisations
preceding the date of the first hospitalisation for compli-
cated peptic ulcer; from these data we computed the
Charlson index score [15]. We defined 3 levels of comor-
bidity: low (index score of 0); moderate (index score of 1–
2); and high (index score of more than 2). For this study,
diagnoses of perforated and bleeding peptic ulcer wereBMC Geriatrics 2007, 7:8 http://www.biomedcentral.com/1471-2318/7/8
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excluded from the Charlson index, since they defined our
study population. Diagnoses of previous uncomplicated
peptic ulcer disease (excluding peptic ulcer bleeding and
perforation) were also removed from the index and
included as a separate variable in the analyses.
Other covariates
Information on use of drugs potentially associated with
both advanced age and a poor outcome of bleeding and
perforated peptic ulcer was obtained through the prescrip-
tion databases of Viborg, North Jutland, and Aarhus coun-
ties. The prescription databases contain information on
all prescriptions redeemed in any pharmacy in the county,
including patient's civil registry number, the type and
amount of drug prescribed and the prescription date [16].
By computerized data linkage we ascertained whether
patients hospitalized with perforated peptic ulcer had
redeemed prescriptions for oral glucocorticoids, low- or
high-dose aspirin and/or NSAIDs within 60 days of
admission. For patients hospitalized with bleeding peptic
ulcer we retrieved information on redeemed prescriptions
for oral glucocorticoids, aspirin, NSAIDs, vitamin K antag-
onists, calcium channel blockers, and antidepressants
within 60 days of admission.
With the exception of aspirin and low-dose (200 mg) ibu-
profen (which accounts for only 14% of ibuprofen use in
Denmark), all included drugs are available in Denmark
on the prescription-only basis [17].
Statistical analysis
Based on the date of first admission with perforated or
bleeding peptic ulcer we constructed Kaplan-Meier sur-
vival curves and life-table estimates of 30-day mortality
for the main study variables: age group (15–64, 65–79,
80+ years), level of comorbidity (according to the Charl-
son score categories), gender, use of ulcer-related drugs,
and previous hospitalisation with uncomplicated peptic
ulcer disease. To compare 30-day mortality in the three
different age groups we first computed standardized 30-
day mortality rates, using direct standardization in the
oldest age groups (65–79 years and 80+ years) to the dis-
tribution of comorbidity, and gender in the youngest age
group (15–64 years). Second, we used Cox's regression
analysis to estimate 30-day mortality rate ratios (MRRs),
while adjusting for comorbidity level, gender, use of ulcer-
related drugs, and previous hospitalisation with uncom-
plicated peptic ulcer disease. To examine the effect of
comorbidity on the association between advanced age
and 30-day mortality, we then stratified the analyses by
the three levels of comorbidity. The Cox's regression anal-
yses were repeated after including comorbidity diagnoses
made during the index hospitalisation with complicated
peptic ulcer. To examine whether age-related mortality
changed during the study period we also stratified the
analyses on calendar year band (1991–1997 vs. 1998–
2004).
The assumption of proportional hazards in the Cox's
regression model was assessed graphically and found
appropriate.
All analyses were performed using SAS version 8.2 (SAS
Institute Inc, Cary, NC).
The study was approved by the Aarhus University Hospi-




Descriptive data are provided in table 1. We identified
2,061 patients with a first-time discharge diagnosis of per-
forated peptic ulcer; of these 1,356 patients (61.4%) were
more than 65 years old and 513 patients (25.7%) were
aged 80+ years. A total of 38.5% of patients had at least
one previous discharge diagnosis included in the Charl-
son comorbidity index and the burden of comorbidity
increased with age. The majority of elderly patients
(74.6% and 81.3% of the 65–79 and 80+ year old, respec-
tively) were current users of NSAIDs, low- or high-dose
aspirin or oral glucocorticoids.
Overall 30-day mortality from perforated peptic ulcer was
25.3%, but it increased from 8.9% among patients
younger than 65 years to respectively 28.5% and 46.0%
among patients aged 65–79 years and 80+ years (table 2).
The standardized 30-day mortality was 24.2% among
patients aged 65–79 years and 44.6% among those aged
80+ years. As seen in figure 1, the higher mortality among
elderly patients was most pronounced during the first 2
weeks of hospitalisation with perforated peptic ulcer. The
adjusted 30-day MRRs were 2.8 (95% CI: 2.1–3.6) among
patients aged 65–79 years and 5.3 (95% CI: 4.0–6.9)
among patients aged 80+ years, each compared with
patients younger than 65 years (table 2). Including
comorbidity diagnoses made during the index hospitali-
sation with perforated peptic ulcer did not change any of
the MRRs. Further, we found no difference in age-related
MRR between calendar year bands, 1991–1997 and
1998–2004 (data not shown). Regardless of comorbidity
level, MRRs were consistently higher among elderly than
among younger patients (table 3). As seen from table 3
the MRRs associated with increased age were highest
among patients with low comorbidity levels. By contrast,
the absolute differences in 30-day mortality between the
three age groups were similar across the comorbidity
index groups.BMC Geriatrics 2007, 7:8 http://www.biomedcentral.com/1471-2318/7/8
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Bleeding peptic ulcer
We identified 7,232 patients with a first-time discharge
diagnosis of bleeding peptic ulcer, of whom 5,146
(71.2%) were older than 65 years of age and 2,372
(32.7%) were aged 80+ years. The prevalence of patients
with comorbidities increased from 31.5% among patients
younger than 65 years to 51.6% among patients aged 80+
years (table 1).
Overall 30-day mortality of bleeding peptic ulcer was
10.8%, but rose from 4.3% among patients younger than
65 years to 10.2% and 17.0% among patients aged 65–79
years and 80+ years, respectively (table 2, figure 1). After
standardization, the 30-day mortality decreased to 8.7%
among the 65–79 year old and to 16.9% among those
aged 80+ years. Adjusted MRRs were 2.2 (95% CI: 1.7–
2.8) and 3.7 (95% CI: 2.9–4.7) among patients aged 65–
79 years and 80+ years compared with patients younger
than 65 years. Including comorbidity diagnosis made dur-
ing the index hospitalisation with bleeding peptic ulcer
did not change any of the MRRs and we found no differ-
ence in age-related MRRs between calendar year bands,
1991–1997 and 1998–2004 (data not shown). The strati-
fied analyses consistently showed higher MRRs among
elderly patients compared with younger patients regard-
less of level of comorbidity (table 3). Again the MRRs
associated with increased age were highest among patients
with low comorbidity level whereas the absolute differ-
ences in 30-day mortality among the three age groups
were similar across the three strata of comorbidity.
Discussion
In this population-based cohort study of more than 9,000
patients we found that elderly patients had substantially
Table 2: Crude and standardized 30-day mortality for patients with a first-time discharge diagnosis of perforated or bleeding peptic 
ulcer and 30-day mortality rate ratios (MRRs) relative to patients aged 15–64.
Age groups Number of patients
N
30-day mortality Standardized 30-day mortality ∞ 
(95% CI)





15–64 805 8.9% 8.9% (7.0%–10.9%) 1 (ref) 1 (ref)
65–79 743 28.5% 24.2% (20.7%–27.6%) 3.5 (2.7–4.6) 2.8 (2.1–3.6)
80+ 513 46.0% 44.6% (38.8%–50.5%) 6.6 (5.1–8.6) 5.3 (4.1–7.0)
Bleeding peptic ulcer
15–64 2086 4.3% 4.3% (3.4%–5.2%) 1 (ref) 1 (ref)
65–79 2774 10.2% 8.7% (7.6%–9.9%) 2.4 (1.9–3.1) 2.2 (1.7–2.8)
80+ 2372 17.0% 16.9% (15.0%–18.7%) 4.2 (3.3–5.3) 3.7 (2.9–4.7)
∞ Standardized to the distribution of gender and comorbidity in the youngest age group.
# Adjusted by Cox regression analysis for gender, comorbidity prior to hospitalisation with complicated peptic ulcer, use of ulcer-related drugs and previous admissions with 
uncomplicated peptic ulcer.
Table 1: Characteristics of 2,061 patients with perforated and 7,232 patients with bleeding peptic ulcer in the counties of North 
Jutland, Aarhus and Viborg, Denmark.














Female 338 (42.0%) 410 (55.2%) 358 (69.8%) 739 (35.5%) 1329 (47.1%) 1402 (59.1%)
Male 467 (58.0%) 333 (44.8%) 155 (30.2%) 1347 (64.6%) 1445 (52.1%) 970 (40.9%)
Ulcer-related drugs*
Use† 484 (60.1%) 554 (74.6%) 417 (81.3%) 1434 (68.7%) 2093 (75.4%) 1950 (82.2%)
No use 321 (39.9%) 189 (25.4%) 96 (18.7%) 652 (31.3%) 681 (24.6%) 422 (17.8%)
Previous uncomplicated peptic ulcer disease
No 709 (88.1%) 657 (88.4%) 463 (90.3%) 1829 (87.5%) 2446 (88.2%) 2115 (89.2%)
Yes 96 (11.9%) 86 (11.6%) 50 (9.7%) 257 (12.6%) 328 (11.8%) 257 (10.8%)
Comorbidity#
Low 616 (76.5%) 378 (50.9%) 273 (53.2%) 1442 (68.2%) 1322 (47.7%) 1148 (48.4%)
Moderate 161 (20.0%) 290 (39.0%) 208 (40.6%) 523 (25.1%) 1139 (41.0%) 1013 (42.7%)
High 28 (3.5%) 75 (10.1%) 32 (6.2%) 141 (6.7%) 313 (11.3%) 212 (8.9%)
*For perforated peptic ulcer "ulcer-related drugs" are: oral glucocorticoids, NSAIDs and aspirin. For bleeding peptic ulcer "ulcer-related drugs" are: 
non-aspirin NSAIDs, aspirin, oral glucocorticoids, vitamin K antagonists, calcium channel blockers, and/or antidepressants
† Use = filled prescription 60 days before admission with perforated peptic ulcer.
# Three levels of the index were defined: Low (no co-morbidity), medium (Charlson index 1–2) and high (Charlson index 2+).BMC Geriatrics 2007, 7:8 http://www.biomedcentral.com/1471-2318/7/8
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increased 30-day mortality of perforated and bleeding
peptic ulcer compared with younger patients. The mortal-
ity increases were most pronounced during the first 14
days following hospitalisation, particularly among
patients with perforated peptic ulcer. An increased burden
of comorbidity among elderly patients did not explain the
association between advanced age and increased mortal-
ity, with the strongest association observed among
patients with no history of hospital-diagnosed comorbid-
ity.
The findings of a higher mortality of perforated and bleed-
ing peptic ulcer among elderly patients corroborate results
of most previous studies [18-21]. However, use of ulcer-
related drugs and comorbidity may have influenced
results of these studies making them difficult to interpret.
No previous studies have focused on age-related increas-
ing level of comorbidity influencing the effect of advanced
age on the outcome after complicated peptic ulcer. Two
recent population-based studies from Scotland and the
Netherlands found that after adjustment for multiple con-
founders, age remained an independent predictor of
death from upper gastrointestinal bleeding [7,10]. In con-
trast, Segal et al. [22] and Antler et al. [23] found similar
mortality rates of upper gastrointestinal bleeding among
young and elderly patients in two observational US stud-
ies, in 1981 and 1996. It is important to recognize that
these data are derived from studies of the outcome of
upper gastrointestinal bleeding, which includes – but is
not confined to – bleeding peptic ulcer. Upper gastroin-
testinal bleeding among young patients is more likely to
be caused by lesions induced by excess alcohol consump-
tion, e.g. oesophageal varices, Mallory-Weiss lesions, or
hemorrhagic gastritis, whereas elderly patients are more
likely to bleed from peptic ulcers [22,24]. Thus, the asso-
ciation between age and the outcome of upper gastroin-
testinal bleeding may be biased by the different spectrum
of bleeding lesions. Few previous studies found comor-
bidity to be an independent prognostic factor for compli-
cated peptic ulcer. A recent Dutch study based on
retrospectively reviewed medical records found that 10 of
13 death following peptic ulcer bleeding were unavoida-
ble primarily because of severe comorbidities [25].
The main strengths of the present study include its large
size and the uniformly organized health system allowing
a population-based design and the use of independent
medical databases, which limits the risk of selection and
information bias. A further advantage is the ability to
adjust the analysis for the pre-hospitalisation use of ulcer-
related drugs, which is an important potential confound-
ing factor. However, residual confounding could stem
from potential misclassification of drug use due to lack of
compliance.
Table 3: 30-day mortality and mortality rate ratios (MRR) for patients with perforated and bleeding peptic ulcer stratified by level of 
comorbidity.
Comorbidity score Ω Age (years) Number of patients 30-day mortality Crude 30-day MRR (95% CI) Adjusted 30-day MRR* (95% CI)
Perforated Peptic ulcer
Low 15–64 616 6.0% 1 (ref) 1 (ref)
65–79 378 20.9% 3.8 (2.5–5.6) 3.5 (2.3–5.1)
80+ 273 41.0% 8.6 (5.9–12.4) 8.1 (5.5–11.9)
Moderate 15–64 161 16.8% 1 (ref) 1 (ref)
65–79 290 34.8% 2.3 (1.5–3.4) 2.1 (1.4–3.2)
80+ 208 50.0% 3.8 (2.5–5.7) 3.4 (2.3–5.3)
High 15–64 28 28.6% 1 (ref) 1 (ref)
65–79 75 42.7% 1.6 (0.8–3.6) 1.6 (0.7–3.6)
80+ 32 62.5% 3.0 (1.3–6.7) 2.9 (1.2–6.8)
Bleeding Peptic ulcer
Low 15–64 1422 3.4% 1 (ref) 1 (ref)
65–79 1322 6.7% 2.0 (1.4–2.9) 1.9 (1.3–2.7)
80+ 1148 16.0% 4.9 (3.6–6.8) 4.5 (3.3–6.2)
Moderate 15–64 523 5.5% 1 (ref) 1 (ref)
65–79 1139 13.4% 2.5 (1.7–3.7) 2.5 (1.7–3.7)
80+ 1012 16.9% 3.2 (2.2–4.8) 3.2 (2.2–4.8)
High 15–64 141 9.2% 1 (ref) 1 (ref)
65–79 313 13.7% 1.5 (0.8–2.8) 1.5 (0.8–2.7)
80+ 212 25.0% 2.9 (1.6–5.1) 2.7 (1.5–4.9)
Ω Three levels of the index were defined: Low (no co-morbidity), medium (Charlson Index 1–2) and high (Charlson Index 3+). * Adjusted in a Cox regression model for 
gender, previous admissions with uncomplicated peptic ulcer and ulcer-related drug use.BMC Geriatrics 2007, 7:8 http://www.biomedcentral.com/1471-2318/7/8
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Survival of patients with perforated (A) and bleeding peptic ulcer (B) according to age group Figure 1
Survival of patients with perforated (A) and bleeding peptic ulcer (B) according to age group. Aarhus, North Jutland and Viborg 
counties, Denmark.
A. Perforated peptic ulcer 
B. Bleeding peptic ulcer BMC Geriatrics 2007, 7:8 http://www.biomedcentral.com/1471-2318/7/8
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We adjusted for level of comorbidity by using the Charl-
son Comorbidity Index. Registration of comorbidities and
therefore control of confounding might have been more
accurate among younger patients; thus, residual con-
founding could cause overestimation of the relative mor-
tality in elderly patients. Coding errors in the routine
hospital discharge data might have lead to over-ascertain-
ment of perforated or bleeding peptic ulcer. However, the
positive predictive value of recorded gastrointestinal site-
specific discharge diagnosis has been reported to be high
[26], and as any misclassification is unlikely to be related
to age the influence on our results should be negligible.
Furthermore, the validity of the methodology used in this
study is backed by a recent Danish government-supported
national health care quality measurement project on out-
come of bleeding and perforated peptic ulcer. Using pro-
spectively collected clinical data, the project found an
overall 30-day mortality very similar to ours, i.e. 28% vs.
25% for perforated and 11% vs.11% for bleeding peptic
ulcer [27].
Comorbidity apparently cannot explain most of the mor-
tality increase among elderly patients with complicated
peptic ulcer disease. Other factors, such as diagnostic dif-
ficulties, treatment differences, clinical quality, as well as
the progressive processes of functional and biological
deterioration associated with advanced age may play a
role [28]. Delayed surgical treatment is a major prognostic
factor for poor outcome of perforated peptic ulcer [29]
and treatment delay may be directly related to age [3,30].
Malnutrition is associated with decreased wound healing,
increased length of hospital stay and increased mortality
in surgical patients [31]. As the prevalence of malnutrition
is markedly higher among elderly patients, it may help
explain the increased mortality among elderly patients.
Sepsis and multi-organ failure are reportedly leading
causes of death in patients with perforated peptic ulcer
[32]. Ageing is associated with complex changes in the
immune system, including an altered acute phase
response, and thus an increased risk of and poorer out-
come after severe infections [33]. Unfortunately, the data-
bases used in this study lack clinical data on treatment
delay or the patients' nutritional status. We were unable to
differentiate which complicated peptic ulcers were rea-
sons for hospitalisation and which cases occurred during
hospitalisation with other diseases. Further studies may
enlighten the role of these factors in the mortality from
complicated peptic ulcer disease in elderly patients.
Conclusion
In conclusion, ageing is a strong predictor for a poor out-
come of perforated and bleeding peptic ulcer independ-
ently of comorbidity.
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